Cargando…

Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS

PURPOSE: The analysis of epidermal growth factor receptor (EGFR) mutations in many patients with advanced non-small-cell lung cancer (aNSCLC) has provided the opportunity for successful treatment with specific, targeted EGFR tyrosine kinase inhibitors. However, this therapeutic decision may be chall...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arriola, E., Paredes-Lario, A., García-Gomez, R., Diz-Tain, P., Constenla, M., García-Girón, C., Márquez, G., Reck, M., López-Vivanco, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153859/ https://www.ncbi.nlm.nih.gov/pubmed/29623586 http://dx.doi.org/10.1007/s12094-018-1855-y

Ejemplares similares

Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs
por: Zhang, Chengjuan, et al.
Publicado: (2017)

Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance
por: Zheng, D., et al.
Publicado: (2016)

Comparison of the SuperARMS and Droplet Digital PCR for Detecting EGFR Mutation in ctDNA From NSCLC Patients
por: Feng, Wei-neng, et al.
Publicado: (2018)

Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer
por: Normanno, Nicola, et al.
Publicado: (2016)

Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?
por: Li, Yi-Ze, et al.
Publicado: (2023)

A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR‐TKI resistance
por: Wang, Wenxian, et al.
Publicado: (2016)

Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors
por: Huang, Chun-Ta, et al.
Publicado: (2023)

The clinical utility of dynamic ctDNA monitoring in inoperable localized NSCLC patients
por: Yang, Yin, et al.
Publicado: (2022)

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain
por: Arriola, Edurne, et al.
Publicado: (2018)

Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC
por: Qiu, Bin, et al.
Publicado: (2021)

Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC)
por: Agulnik, Jason S., et al.
Publicado: (2022)

Evaluation of liquid based cytology in detection of EGFR mutation in NSCLC by large samples
por: Dong, Zhengwei, et al.
Publicado: (2020)

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset
por: Nishio, Kazuto, et al.
Publicado: (2021)

Presence of mEGFR ctDNA predicts a poor clinical outcome in lung adenocarcinoma
por: Kim, Taehee, et al.
Publicado: (2019)

Prognostic Value of Circulating Tumor DNA (ctDNA) in Oncogene-Driven NSCLC: Current Knowledge and Future Perspectives
por: Zografos, Eleni, et al.
Publicado: (2022)

State of the Art: ctDNA in Upper Gastrointestinal Malignancies
por: Labiano, Ibone, et al.
Publicado: (2023)

EGFR circulating tumour DNA testing: identification of predictors of ctDNA detection and implications for survival outcomes
por: Pender, Alexandra, et al.
Publicado: (2020)

The Potential Use of Dynamics Changes of ctDNA and cfDNA in the Perioperative Period to Predict the Recurrence Risk in Early NSCLC
por: Zhao, Xiaolong, et al.
Publicado: (2021)

ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors
por: Nie, Wei, et al.
Publicado: (2022)

Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy
por: Falk, Markus, et al.
Publicado: (2023)

Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC
por: Gaber, Rania, et al.
Publicado: (2014)

Role of ctDNA in Breast Cancer
por: Sant, Marta, et al.
Publicado: (2022)

The Role of ctDNA in Gastric Cancer
por: Mencel, Justin, et al.
Publicado: (2022)

Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples
por: Gumà, Josep, et al.
Publicado: (2022)

Effect of icotinib on advanced lung adenocarcinoma patients with sensitive EGFR mutation detected in ctDNA by ddPCR
por: Chen, Hua-Fei, et al.
Publicado: (2019)

EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome
por: Vendrell, Julie A., et al.
Publicado: (2021)

Postoperative ctDNA detection predicts relapse but has limited effects in guiding adjuvant therapy in resectable stage I NSCLC
por: Wang, Bolin, et al.
Publicado: (2023)

Comparison of the SuperARMS and ARMS for detecting EGFR mutations in liquid-based cytology specimens from NSCLC patients
por: Wu, Wei, et al.
Publicado: (2020)

Short report: Performance evaluation of the Idylla™ KRAS and EGFR mutation tests on paraffin-embedded cytological NSCLC samples
por: Offerman, Saskia, et al.
Publicado: (2021)

ctDNA as a biomarker of progression in oesophageal adenocarcinoma
por: Bonazzi, V.F., et al.
Publicado: (2022)

Detection of epidermal growth factor receptor (EGFR) mutations from preoperative circulating tumor DNA (ctDNA) as a prognostic predictor for stage I–III non-small cell lung cancer (NSCLC) patients with baseline tissue EGFR mutations
por: Guo, Kai, et al.
Publicado: (2021)

Construction of a reference material panel for detecting KRAS/NRAS/EGFR/BRAF/MET mutations in plasma ctDNA
por: Xu, Jun, et al.
Publicado: (2021)

NGS-Based ctDNA Profiling After the Resistance of Second-Line Osimertinib for Patient with EGFR-Mutated Pulmonary Adenocarcinoma
por: Li, Dan, et al.
Publicado: (2021)

Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR‐mutant non‐small cell lung cancer
por: Janssen, Julie M., et al.
Publicado: (2022)

Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice
por: Cho, Byoung Chul, et al.
Publicado: (2022)

Detection of somatic mutations in ctDNA derived from adenocarcinoma patients – EGFR tyrosine kinase inhibitor monitoring preliminary study
por: Lewandowska, Marzena Anna, et al.
Publicado: (2019)

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset
por: Ohe, Yuichiro, et al.
Publicado: (2018)

Liquid Biopsy, ctDNA Diagnosis through NGS
por: Lin, Chen, et al.
Publicado: (2021)

Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients
por: Provencio, Mariano, et al.
Publicado: (2017)

ctDNA-Profiling-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among TP53-Negative NSCLC Patients
por: Lu, Jun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7k5updggo25o5vef14ug2oaqki